← Back to Clinical Trials
Recruiting NCT06261398

NCT06261398 Better Birth Outcomes Through Technology, Education, and Reporting

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06261398
Status Recruiting
Phase
Sponsor Ohio State University
Condition Pregnancy
Study Type INTERVENTIONAL
Enrollment 550 participants
Start Date 2024-02-26
Primary Completion 2027-09

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
BETTER: motivational interviewing and text messagingStandard of care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 550 participants in total. It began in 2024-02-26 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a pragmatic randomized control trial to evaluate the BETTER intervention compared to standard obstetrical care (control) to determine whether it helps to reduce maternal anemia and other adverse pregnancy outcomes. The BETTER intervention includes one motivational interviewing session and bi-weekly text messages to encourage patients to connect with resources that address their social needs, including housing, food, and transportation. Quantitative data will be used to study participant outcomes, including surveys, and electronic health record data.

Eligibility Criteria

Inclusion Criteria * Less than 20 weeks and 6 days pregnant upon enrollment * At least 18 years of age * Receiving obstetric care at OSU McCampbell Hall or OSU Outpatient Care East * Singleton pregnancy and fetus with a heartbeat * English speaking * Able to receive text messages Exclusion Criteria * Has a significant medical condition (eg sickle cell disease) that is a cause of anemia * Has a plan for transfusion during pregnancy

Contact & Investigator

Central Contact

Ann McAlearney, ScD, MS

✉ Ann.McAlearney@osumc.edu

📞 614-293-3716

Principal Investigator

William Grobman, MD, MBA

PRINCIPAL INVESTIGATOR

Ohio State University

Frequently Asked Questions

Who can join the NCT06261398 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06261398 currently recruiting?

Yes, NCT06261398 is actively recruiting participants. Contact the research team at Ann.McAlearney@osumc.edu for enrollment information.

Where is the NCT06261398 trial being conducted?

This trial is being conducted at Columbus, United States, Columbus, United States, Columbus, United States.

Who is sponsoring the NCT06261398 clinical trial?

NCT06261398 is sponsored by Ohio State University. The principal investigator is William Grobman, MD, MBA at Ohio State University. The trial plans to enroll 550 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology